Hemogenyx Advances CAR-T Trial with New Dose Level and Pediatric Recruitment

Hemogenyx Pharmaceuticals advances its Phase I clinical trial of HG-CT-1, a CAR T cell therapy for acute myeloid leukemia, with new dose levels and pediatric recruitment approved by the Data monitoring committee.

• The independent Data Safety Monitoring Board approved the progression to the next dose level of HG-CT-1, a CAR T cell therapy, intended for treating acute myeloid leukemia.
• Hemogenyx Pharmaceuticals announced the recruitment of pediatric patients for the ongoing phases of clinical research, expanding the trials scope and potential impact.
• The company also granted restricted share units to its team, signaling confidence in the ongoing development of its medication amid promising trial advancements.